[{"address1": "301 Binney Street", "address2": "3rd Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 259 3860", "website": "https://scholarrock.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 150, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay Thomas Backstrom M.D., M.P.H.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1071673, "exercisedValue": 0, "unexercisedValue": 3439375}, {"maxAge": 1, "name": "Mr. Edward H. Myles MBA", "age": 52, "title": "CFO, COO & Treasurer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 720786, "exercisedValue": 0, "unexercisedValue": 857292}, {"maxAge": 1, "name": "Ms. Tracey M. Sacco M.B.A.", "age": 48, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 548855, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mo  Qatanani Ph.D.", "age": 51, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rushmie  Nofsinger", "title": "Vice President of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Junlin  Ho J.D.", "age": 45, "title": "General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 563729, "exercisedValue": 0, "unexercisedValue": 112564}, {"maxAge": 1, "name": "Ms. Caryn  Parlavecchio", "age": 52, "title": "Chief Human Resources Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa Amaya Price", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Moore CPA", "age": 49, "title": "Senior Vice President of Finance", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Iarrobino", "title": "Senior Vice President of Clinical Development & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 37.63, "open": 37.85, "dayLow": 36.46, "dayHigh": 38.61, "regularMarketPreviousClose": 37.63, "regularMarketOpen": 37.85, "regularMarketDayLow": 36.46, "regularMarketDayHigh": 38.61, "beta": 0.508, "forwardPE": -16.627718, "volume": 488586, "regularMarketVolume": 488586, "averageVolume": 1045606, "averageVolume10days": 835490, "averageDailyVolume10Day": 835490, "bid": 36.98, "ask": 37.14, "bidSize": 100, "askSize": 200, "marketCap": 3470308096, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 46.98, "fiftyDayAverage": 42.1989, "twoHundredDayAverage": 21.698275, "currency": "USD", "enterpriseValue": 3397847296, "floatShares": 72816517, "sharesOutstanding": 93615000, "sharesShort": 15600497, "sharesShortPriorMonth": 15355312, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.1666, "heldPercentInsiders": 0.011390001, "heldPercentInstitutions": 1.1752601, "shortRatio": 15.11, "shortPercentOfFloat": 0.3084, "impliedSharesOutstanding": 93615000, "bookValue": 0.989, "priceToBook": 37.482304, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -225966000, "trailingEps": -2.36, "forwardEps": -2.15, "enterpriseToEbitda": -14.869, "52WeekChange": 1.5069954, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SRRK", "underlyingSymbol": "SRRK", "shortName": "Scholar Rock Holding Corporatio", "longName": "Scholar Rock Holding Corporation", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d4172360-ba22-3374-b294-8dd0e33412b6", "messageBoardId": "finmb_548810128", "gmtOffSetMilliseconds": -18000000, "currentPrice": 37.07, "targetHighPrice": 57.0, "targetLowPrice": 39.0, "targetMeanPrice": 48.75, "targetMedianPrice": 50.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 139064992, "totalCashPerShare": 1.485, "ebitda": -228515008, "totalDebt": 66606000, "quickRatio": 3.561, "currentRatio": 3.884, "debtToEquity": 84.103, "returnOnAssets": -0.671, "returnOnEquity": -1.8307099, "grossProfits": -169146000, "freeCashflow": -102019128, "operatingCashflow": -188784992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]